Home » NICE Says Eli Lilly’s Breast Cancer Treatment Isn’t Cost-Effective
NICE Says Eli Lilly’s Breast Cancer Treatment Isn’t Cost-Effective
NICE did not recommend Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) for use by the UK’s National Health Service as an endocrine-based therapy for adults with breast cancer.
The drug appeared to work as well as other first treatments for locally advanced or metastatic, hormone receptor-positive, HER2-negative breast cancer, but NICE said it wasn’t cost-effective compared to other treatments that have already been granted approval on NHS.
Eli Lilly has not publicly disclosed the drug’s price.
Upcoming Events
-
07May
-
14May
-
30May